AstraZeneca Plc AZN received two significant regulatory updates from the U.S. Food and Drug Administration, with its cancer ...
AstraZeneca has received US FDA approval for TRUQAP (capivasertib) as the first targeted treatment for PTEN-deficient ...
Newly published data convinced AstraZeneca to conduct a sprawling late-stage program for its GLP-1 pill. Elsewhere, Bausch + ...
AstraZeneca CEO Pascal Soriot Updates On Chinese Compliance Probe And Lung Cancer Drug Trial Results
Recently, Chinese authorities detained some current and former employees of AstraZeneca Plc (NASDAQ:AZN) as part of a broader investigation into alleged illegal activities in the pharmaceutical sector ...
AstraZeneca said the U.S. FDA has extended the decision date for its camizestrant new drug application, which seeks approval of the oral SERD in combination with CDK4/6 inhibitors as a first-line ...
The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's ...
AstraZeneca cooperating with Chinese authorities Update on investigation reassures market Potential fines of 1-5 times unpaid tax Company forecasts robust 2025 growth Shares up 5% at 1105 GMT Feb 6 ...
AstraZeneca AZN announced two positive regulatory updates from the FDA for its cancer drugs namely Lynparza and Imfinzi The FDA granted priority review for the supplemental new drug application (sNDA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results